Cytori Therapeutics Management To Discuss Scleroderma Clinical Trial Findings

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) will host a live webcast to discuss the two year follow-up results from the SCLERADEC I trial for scleroderma. There will also be time allocated for Q&A. The academic presentation of the trial findings is scheduled for Saturday, February 20, 2016 at the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, and will be presented by trial co-principal investigator Dr. Guy Magalon.